%0 Journal Article
%B Circulation
%D 2019
%P 739 - 750
%T Canagliflozin and Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus and Chronic Kidney Disease in Primary and Secondary Cardiovascular Prevention Groups
%V 140